Elinzanetant: all 23 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study ParticipantsRecruitingNCT07762287Phase 1
• A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With MenopauseCompletedNCT06112756Phase 2Results posted
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerActive, not recruitingNCT05587296Phase 3Results posted
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)CompletedNCT05099159Phase 3Results posted
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the MenopauseCompletedNCT05042362Phase 3Results posted
• A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the MenopauseCompletedNCT05030584Phase 3Results posted
• A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor SymptomsCompletedNCT03596762Phase 2Results posted
• Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor SymptomsCompletedNCT02865538Phase 1/2Results posted
• A Study to Learn if Elinzanetant Affects the Ability to Drive and Brain Function in Healthy WomenCompletedNCT06219902Phase 1
• A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy ParticipantsCompletedNCT05481528Phase 1
• A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female ParticipantsCompletedNCT05471817Phase 1
• A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 YearsCompletedNCT05381142Phase 1
• A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male ParticipantsCompletedNCT05351892Phase 1
• A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work NormallyCompletedNCT05071729Phase 1
• A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female AdultsCompletedNCT04981431Phase 1
• A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female ParticipantsCompletedNCT04903821Phase 1
• A Study to Learn How Much Rosuvastatin Gets Into the Blood When Taken With or Without Elinzanetant and to Learn About the Safety of Elinzanetant in Healthy ParticipantsCompletedNCT04889287Phase 1
• Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the BodyCompletedNCT04845841Phase 1
• Mass Balance Study of [14C]-NT-814 Oral Suspension in Healthy Male SubjectsCompletedNCT04654897Phase 1
• NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical StudyWithdrawnNCT02692157Phase 1/2
• First Time in Human Study (FTIH) With Positron Emission Tomography (PET)CompletedNCT01381419Phase 1
• A Repeat Dose Positron Emission Tomography Study With GSK1144814CompletedNCT01209039Phase 1
• Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy SubjectsCompletedNCT01090440Phase 1

← Elinzanetant overview